Log inTry free

Ocular Therapeutix (OCUL) stock

Market cap $1.6B

$6.96
-4.53%

Market closed. Prices as of Friday's close.

Quality Score
-10
Poor
In its industry
#298of 300
Biotech

OCUL's Quality Score fell 2 points on Fri, Oct 2, to -10.

NextQ4 2026“AXPAXLI™ wet AMD NDA submission on track for Q4 2026…”Filing with regulators · 8-K, Aug 3
Cash$599M, about 10 quarters (2.5 years) at the last year's spendingOn Jun 30 · the company says “into 2028”

Follow OCUL's trial news. Pro members can get an alert when Ocular Therapeutix files news, and see its trials, share raises, and its CEO's filings.

Get an optional alert when OCUL files news on its trialsSee it live, free until tomorrow morning. No account. No card. Then keep going with a free account.

We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.

Cash$599M, about 10 quarters (2.5 years) at the last year's spendingOn Jun 30 · the company says “into 2028”

What's next for OCUL, and how long its cash lasts

From Ocular Therapeutix’s SEC filings and ClinicalTrials.gov: the company’s own words, the registry’s dates, and arithmetic, not a forecast. Companies often miss their own dates.

Next step the company has named

Q4 2026“AXPAXLI™ wet AMD NDA submission on track for Q4 2026 following positive Type C Meeting with the U.S. FDA in May 2026”Filing with regulators · 8-K, Aug 3

What it means: a filing asks regulators to approve a drug for sale. Once it is complete and accepted, the FDA sets a decision date, and we show it here.

A trial underway
Efficacy and Safety of Intravitreal OTX-TKI (Axitinib Implant) in Subjects With Neovascular Age- Related Macular DegenerationPhase 3 · Active · 825 people · main data estimated Jan 8, 2027 · NCT06495918

3 more trials, 30 filings, for Pro members.

Cash runway Jun 30 balance sheet

About 10 quarters

$599M in cash and short-term investments, at its spending over the last year

What it means: how long the cash would last at the same pace, before any new money. The company's own estimate is “into 2028” (8-K, Aug 3).

For Pro members: the cash used each quarter, and the math.

Dilution on the horizon

  • Shelf registration (S-3ASR, filed Sep 30, 2025)

A shelf lets a company sell shares later; an at-the-market program sells them into the market over time. Neither is a sale by itself.

For Pro members: 2 raises and their amounts, and the share count against a year ago.

Insiders

Chief Operating Officer Donald Notman sold 1,099 shares on Aug 31. 20 more insider trades this year.

From their own Form 4 filings: buys and sales in the market, not awards or shares withheld for tax.

Get an optional alert when Pravin Dugel buys or sells

For Pro members: every trade, and Pravin Dugel’s 15 filings and quotes.

Get an optional alert when OCUL files news on its trialsSee it live, free until tomorrow morning. No account. No card. Then keep going with a free account.

See every upcoming FDA date →

FDA dates in the next 60 days

Decision dates and advisory committee meetings the companies have announced in their own filings, soonest first and small companies first.

DateStockDrug

8 more FDA dates and 114 trial data dates in the next 60 days. Pro members see every one, with the cash against its date and an optional alert before it. Get in free →

Why OCUL is down

Ocular Therapeutix fell 20.7% on Sep 28.

Biotech stocks rose a median 0.4% and the S&P 500 fell 0.7% that day; Ocular Therapeutix fell 20.7%.

Sources: Price history, Sep 28, 2026

−3Long-term trend below a falling 200-day average, down over one year, down over two years

1 more driver, the timeline, and the peer table, for Pro members

5 more things pulling OCUL's score down, for Pro members

What's next

Thu Oct 8: Eyecelerator @ AAO 2026Industry event · date confirmed.

Expected to report Wed Nov 4, before the open

After its last 4 reports it closed +0.5% on average, higher 2 of 4 times.

2 more dates ahead for Pro members: conferences

What would turn OCUL's score around: 9 things, for Pro members

Alert me when OCUL's Quality Score turns up

See it live, free until tomorrow morning. No account. No card. Then keep going with a free account.

Here is what Pro members see.

  • The same page for Pro members, on AMD

    Its Quality Score and rank, the line that drives it, and the live price with the bid and ask.

  • The full chart

    A year of candles to start, out to the whole history, with insider trades marked and the Quality Score under the price.

  • Every line of the score

    Price action, the company, and signals, each with its points, on OCUL and every other stock.

  • FDA dates, counted down

    Each date in the company's own words, its cash against the date, and an optional alert before it.

  • Why a stock ranks

    Its Quality Score, its rank, and the reasons behind it, on one card.

  • CEOs buying their own stock

    Every CEO buy, biggest names first. Sort, filter, download a CSV, and set optional alerts.

  • Congress trades

    Each member's trades. Sort, filter, download a CSV, and set optional alerts.

  • All 14 chart checks

    Trend, volume, tight range, and buying, each lit when it fires, its rule a tap away.

  • Earnings, week by week

    Who reports each day, and how each stock took its last four reports. Optional alerts before them.

  • The market map

    Every stock a box, colored by its Quality Score.

  • Themes, ranked live

    AI chips, quantum, nuclear, defense, space, and more, each stock ranked by its Quality Score.

  • The top 10, every day

    The ten highest Quality Scores at each close, kept day by day, week by week.

  • Optional alerts, your way

    Pick a stock, a score, a price, a filing, or a whole scan. It tells you by push, email, or the bell.

  • Your watchlist, scored

    Your stocks by Quality Score, today's move, or name, with optional alerts.

  • A trade plan, from the chart

    Entry, stop, and two targets on every stock's page. Type your risk and it sizes the trade.

  • On your phone and your laptop

    The same account and watchlist on both, each laid out for its screen.

  • Prices refresh every 2.5 seconds during market hours.
  • Optional alerts by push, email, or the bell.
  • Add it to your Home Screen and it opens like an app.

Nothing is firing on OCUL right now

One per group is shown here.

Trend1 of 5 shown
MA FAN21 EMAW.EMAHH/HL52W HI

Averages stacked in order, price near its high.

Volume1 of 3 shown
VOLVDUU/D VOL

Heavy volume on the run, quiet volume at rest.

Tight range1 of 3 shown
ATR SQZSQUEEZENR7

The daily range is tight against its own recent history.

Buying1 of 3 shown
OBV+CLOSE HISPRING

Closes near the high, and buyers step in on dips.

The other 10 checks on OCUL, and all 14 on every stock.Get in free →

Also on the chart

Not scored

Shown for reference. None of these counts toward the Quality Score: in our tests on 20 years of daily prices, none of them improved it.

  • RSI 1425.3

    Below 30.

  • MACD (12, 26, 9)Below signal

    Crossed below its signal line 16 sessions ago.

  • 50-day average$9.76

    The price is 28.7% below it.

  • 200-day average$9.63

    The price is 27.7% below it. The 50-day is above the 200-day, since Sep 22.

  • ADX 1426.4

    25 or more, with +DI below -DI.

  • Support$6.23

    Swing low from Feb 17, 10.5% below the price.

  • Resistance$9.27

    Swing high from May 29, 33.2% above the price.

  • Bollinger Bands (20, 2)Below

    The bands run from $6.98 to $12.31.

  • Volume1.5x

    Against its 20-day average, for the time of day.

How OCUL ranks in Biotech

OCUL is #298 of 300 by Quality Score. The top three are shown with their scores, and more by name.

More in Biotech, on the Healthcare page

When does OCUL report earnings, and what happens after?

Expected to report Wed Nov 4, before the open (in 30 days). Not yet confirmed by the company.

ReportedGapReaction5 sessions
Aug 3, 2026Before open+1.4%+2.8%+12.5%
May 5, 2026Before open-4.4%-0.6%-5.0%
Feb 5, 2026Before open+3.5%+4.2%+7.1%
Nov 4, 2025Before open-1.8%-4.5%-5.1%

The gap is the next open against the close before the report; the reaction is where that session closed. OCUL closed higher after 2 of its last 4. Past behavior, not a forecast.

Report dates and past reactions come from sessions that have already closed, so none of these figures move.

Who is trading OCUL

OCUL insider trades

One insider sold $11K across 1 filing in the last 6 months. No open-⁠market buys on record. The newest:

SellDonald Notman$11KChief Operating Officerat $10.24 on Aug 31, filed Sep 2

An insider has two business days to file a Form 4, so the trade is already days old when it becomes public. Shown as filed, with no delay.

About Ocular Therapeutix

Ocular Therapeutix Inc is a biotechnology company that specializes in therapies for diseases and conditions of the eye. The company uses its proprietary hydrogel platform technology to deliver therapeutic agents to the eye. Its pipeline consists of eye medication that aims to overcome the limitations of current eye-drop-based therapies for ophthalmic diseases and conditions. Its pipeline product includes Dextenza, OTX-TIC, OTX-TKI, and OTX-IVT.

325 employeesBedford, MAocutx.com

Pro members see every line of every stock's score.

  • Real-⁠time prices, no delay
  • Every line of OCUL's score, with the points and the reason
  • All 14 checks on OCUL and on all 3,243 stocks
  • Every stock ranked, with the chart
  • Every filing, and optional alerts on OCUL
BreakawaySep 2Donald Notman sold OCUL$11K at $10.24, filed Sep 2

What a filing on OCUL would have sent. Alerts are optional.

See all 14 checks on OCULSee it live, free until tomorrow morning. No account. No card. Then keep going with a free account.

Straight Answers

Are the prices delayed?

Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.

Where does the data come from?

Daily bars, quotes, reference data, headlines, and short interest come from Massive, formerly Polygon, a licensed market data vendor. The age of the quotes is shown at the top of every page. Insider trades, notable holders and profits come straight from the SEC. That means Form 4 filings, 13F filings and XBRL financial data on EDGAR. Government filings come from the public STOCK Act and Office of Government Ethics disclosures. The market-wide headlines on the market line also come from the public headline feeds CNBC, MarketWatch and Yahoo Finance publish, shown as the headline, the source and a link to the article. Splits, dividends, and the financial statements on each ticker page come from the vendor's reference data. The 8-K filings on EDGAR are read for the items that move a price. Five years of history is loaded for every stock. So the 200-day and 52-week checks rest on real history. Options flow is not part of the product.

Do I need an account?

Not to start. Tap any green button and you're in, free, with no email and no password. To keep going, create a free account with Google, Apple, or your email. There is no password to make up.

Is this investment advice?

No. It is a screening tool that scores stocks on the chart, the company's own results, and the news and filings. It does not know your situation and it is not a recommendation to buy or sell anything. Please do your own research.

The price, the score, the chart checks and readings, and the industry rank on this page are delayed at least 15 minutes. Filings are shown as filed, because a disclosure is already days or weeks old when it becomes public. Earnings dates and past reactions are settled sessions.